Pancragen

What is it?

Pancragen is a Khavinson tetrapeptide for the pancreas — part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Ovagen and Livagen. It’s a framework-level compound only: the metabolic/beta-cell angle is an interesting hook if it ever gets real data, but right now there is none.

What does it do in my body?

Claimed mechanism: like the rest of the Khavinson family, Pancragen is proposed to act at gene-promoter regions in pancreatic cells, modulating proteins involved in insulin secretion and beta-cell maintenance. This is the family-wide theoretical mechanism applied to the pancreas as the target organ — there is no Pancragen-specific mechanistic study to cite.

How can it help me?

• Where the science stands: Site tier Anecdotal, 0 studies cited — “no published clinical studies were found on PubMed”

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

No adverse-event data exists for Pancragen. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and a peptide with zero published studies is an especially easy target for mislabeling since there’s no literature to check a seller’s claims against at all. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Pancragen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.

Typical dosing

Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.

Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.

There is no dosing or cycling data specific to Pancragen — with zero published studies, there is no dose-finding work of any kind. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Pancragen specifically.

What should I avoid combining — and what's synergistic?

Pancragen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

How can I buy this?